Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sutro Biopharma ( (STRO) ) has shared an update.
On September 29, 2025, Sutro Biopharma announced an organizational restructuring to prioritize its three preclinical ADC programs and research collaborations, aiming to extend its financial runway into mid-2027. The restructuring involves a workforce reduction of about one-third and is expected to result in cost savings and milestone payments, with initial clinical data from its STRO-004 ADC anticipated in 2026.
The most recent analyst rating on (STRO) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Sutro Biopharma stock, see the STRO Stock Forecast page.
Spark’s Take on STRO Stock
According to Spark, TipRanks’ AI Analyst, STRO is a Neutral.
Sutro Biopharma’s overall stock score is primarily impacted by its financial instability and negative valuation metrics. Despite strong revenue growth, the company’s ongoing losses and negative equity position pose significant risks. Technical indicators suggest potential oversold conditions, but bearish long-term momentum persists. The lack of earnings call and corporate events data limits further insights.
To see Spark’s full report on STRO stock, click here.
More about Sutro Biopharma
Sutro Biopharma, Inc. is an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs). The company is advancing a next-generation ADC platform designed to deliver single- and dual-payload ADCs, targeting large oncology markets with limited treatment options and significant need for improved therapies.
Average Trading Volume: 503,593
Technical Sentiment Signal: Sell
Current Market Cap: $75.16M
See more data about STRO stock on TipRanks’ Stock Analysis page.